Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Phenylurea Compounds/administration & dosage"'
Autor:
Valérie Vilgrain, Helena Pereira, Eric Assenat, Boris Guiu, Alina Diana Ilonca, Georges-Philippe Pageaux, Annie Sibert, Mohamed Bouattour, Rachida Lebtahi, Wassim Allaham, Hélène Barraud, Valérie Laurent, Elodie Mathias, Jean-Pierre Bronowicki, Jean-Pierre Tasu, Rémy Perdrisot, Christine Silvain, René Gerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Frédéric Oberti, Olivier Couturier, Isabelle Brenot-Rossi, Jean-Luc Raoul, Anthony Sarran, Charlotte Costentin, Emmanuel Itti, Alain Luciani, René Adam, Maïté Lewin, Didier Samuel, Maxime Ronot, Aurelia Dinut, Laurent Castera, Gilles Chatellier, Elisabeth Delhom - Christol, Alina D Ilonca, Julie Lonjon, Mohamed Abdel-Rehim, Arnaud Dieudonné, Christophe Bazin, Carine Chagneau-Derrode, Patrick Borentain, Antoine Bouvier, Laurent Vervueren, Julia Chalaye, Hicham Kobeiter, Julien Edeline, Etienne Garin, Yan Rolland, Isabelle Archambeaud, Thomas Eugene, Eric Frampas, Christophe Cassinotto, Martine Guyot, Jean-Baptiste Hiriart, Bruno Lapuyade, Julien Vergniol, Philippe Bachellier, Julien Detour, Bernard Duclos, Michel Greget, Francois Habersetzer, Alessio Imperiale, Philippe Merle, Agnès Rode, Julie Morvan, Eric Nguyen-Khac, Thierry Yzet, Guillaume Baudin, Patrick Chevallier, Abakar Mahamat, Thierry Piche, Micheline Razzouk, Patrick Hillon, Romaric Loffroy, Michel Toubeau, Julie Vincent, Gabriele Barabino, Nadia Bouarioua, Muriel Cuilleron, Marie Ecochard, Nathalie Prevot-Bitot, Vincent Leroy, Julie Roux, Christian Sengel, Valérie Bourcier, Nathalie Ganne-Carrie, Olivier Seror, Sylvie Costo, Thông Dao, Jean-Pierre Pelage, Jérôme Dumortier, Francesco Giammarile, Pierre-Jean Valette, Nadia Ghazzar, Olivier Pellerin, Julien Taieb, Pierre Weinmann, Alexandra Heurgue-Berlot, Claude Marcus, Daniele Sommacale, Maria-Angéla Castilla-Lièvre, Sophie Maitre, Lysiane Marthey
Publikováno v:
Lancet Oncology
Lancet Oncology, Elsevier, 2017, 18 (12), pp.1624-1636. ⟨10.1016/S1470-2045(17)30683-6⟩
Lancet Oncology, Elsevier, 2017, 18 (12), pp.1624-1636. ⟨10.1016/S1470-2045(17)30683-6⟩
Summary Background Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ( 90 Y) resin mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37960b5209b2b33f51aee9e80e06e797
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01727346
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01727346
Autor:
Pierre Laurent-Puig, Sylvain Poujol, Françoise Desseigne, S. Thezenas, Thibault Mazard, Evelyne Crapez, Emmanuelle Samalin, E. Francois, Antoine Adenis, T. Conroy, J.F. Seitz, Julien Taieb, M.P. Galais, Jaafar Bennouna, F. Boissière, Marc Ychou, Eric Assenat, O. Bouche, Frédéric Bibeau
Publikováno v:
British Journal of Cancer
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 2014, 110, pp.1148--54. ⟨10.1038/bjc.2013.813⟩
Breast Cancer Research and Treatment, Springer Verlag, 2014, 110, pp.1148--54. ⟨10.1038/bjc.2013.813⟩
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 2014, 110, pp.1148--54. ⟨10.1038/bjc.2013.813⟩
Breast Cancer Research and Treatment, Springer Verlag, 2014, 110, pp.1148--54. ⟨10.1038/bjc.2013.813⟩
IMPACT: 5.922; International audience; BACKGROUND: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de27d5b42bd45149c4970a8cb5a2512
http://europepmc.org/articles/PMC3950852
http://europepmc.org/articles/PMC3950852
Autor:
Antoine Hollebecque, Sonia Extremera, Gilles Salles, Vicente Alfaro, Sandrine Aspeslagh, Mark N. Stein, Emmanuel Gyan, Salvador Fudio, Rastilav Bahleda, Arturo Soto-Matos, Jean-Charles Soria
Publikováno v:
Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩
International audience; This phase I trial evaluated the combination of the marine-derived cyclodepsipeptide plitidepsin (trade name Aplidin) with sorafenib or gemcitabine in advanced cancer and lymphoma patients. The study included two treatment arm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23b85d24896c8e6b050b4cfb9ec050c
https://hal.archives-ouvertes.fr/hal-01791282
https://hal.archives-ouvertes.fr/hal-01791282
Autor:
Lieveke Ameye, Raphaël Maréchal, Amélie Deleporte, Irina Vierasu, Erwin Woff, Thomas Guiot, Camilo Garcia, Alain Hendlisz, Thierry Delaunoit, Gauthier Demolin, Namur Gauthier, Renaud Lhommel, Patrick Flamen, Marc Van den Eynde, Stéphane Holbrechts
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 43, p. 1792-1801 (2016)
European journal of nuclear medicine and molecular imaging, 43 (10
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 43, p. 1792-1801 (2016)
European journal of nuclear medicine and molecular imaging, 43 (10
Introduction: The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0aa1f3a5363635b991f75146123099
https://pubmed.ncbi.nlm.nih.gov/27072811
https://pubmed.ncbi.nlm.nih.gov/27072811
Autor:
Thomas Hundsberger, Dietrich Py, N. Dunkel, A. Ben Aissa, Maria Vargas, Andreas F. Hottinger, Karl Lothard Schaller, Vittoria Espeli, Nicolas Mach, D. Squiban, Damien C. Weber, A Bodmer
Publikováno v:
British Journal of Cancer, vol. 110, no. 11, pp. 2655-2661
British Journal of Cancer
British Journal of Cancer, Vol. 110, No 11 (2014) pp. 2655-2661
British Journal of Cancer
British Journal of Cancer, Vol. 110, No 11 (2014) pp. 2655-2661
BACKGROUND: Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-lab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5769967950cf20f0072e4f151af7bd83
https://serval.unil.ch/resource/serval:BIB_A3EE92645B9C.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_A3EE92645B9C.P001/REF.pdf
Autor:
Céline Gongora
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2014, 13, pp.764. ⟨10.1158/1535-7163.MCT-13-1026⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2014, 13, pp.764. ⟨10.1158/1535-7163.MCT-13-1026⟩
We are aware that sorafenib binds to plasma proteins. At steady state, when sorafenib is orally administered at 800 mg/d, accumulation ratios are 5.7 to 6.4, indicating that it has a good distribution range. Of note, 90% of sorafenib is bound to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f54a702471cb25ea39806909e64549
https://hal.umontpellier.fr/hal-02168059
https://hal.umontpellier.fr/hal-02168059
Autor:
Pascal Wolter, Alexandra Karadimou, Jean-Jacques Body, Patrick Schöffski, H. Van Poppel, Ludo Willems, Benoit Beuselinck, Philip R. Debruyne, Annick Rogiers, T. van Cann, R. Elaidi, Robert Paridaens, Herlinde Dumez, Joost Berkers, Evelyne Lerut
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 107 (10
British Journal of Cancer, 107 (10
The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates cou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdb22c4137af4f142fa2a48d0882b042
https://pubmed.ncbi.nlm.nih.gov/23132391
https://pubmed.ncbi.nlm.nih.gov/23132391